Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Medical Microbiology and Immunology
Published in: Medical Microbiology and Immunology 1/2015

Open Access 01-02-2015 | Review

Toll-like receptor (TLR)-mediated innate immune responses in the control of hepatitis B virus (HBV) infection

Authors: Ejuan Zhang, Mengji Lu

Published in: Medical Microbiology and Immunology | Issue 1/2015

Login to get access

Abstract

The role of adaptive immune responses in the control of hepatitis B virus (HBV) infection is well accepted. The contribution of innate immune responses to the viral control is recognized but yet not fully understood. Toll-like receptors (TLRs) sense pathogen-associated molecule patterns and activate antiviral mechanisms including the intracellular antiviral pathways and the production of antiviral effectors like interferons (IFNs) and pro-inflammatory cytokines. Activation of the TLR3 pathway and the production of IFN-β represent one of the major mechanisms leading to the suppression of HBV replication in the liver, as shown in different in vitro and in vivo models. TLR4 signaling and TLR2 signaling result in the activation of intracellular pathways including MAPK and PI-3 K/Akt in hepatocytes and reduce HBV replication in an IFN-independent manner. HBV is able to counteract the actions of TLR3 and TLR2/4 through downregulation of TLR expression and attenuation of the cellular signaling pathways. Thus, TLR ligands are promising candidates as immunomodulators and therapeutics for the treatment of chronic HBV infection. Specific antiviral treatment against HBV could recover the TLR functions in chronic HBV infection and increase the effectiveness of therapeutic approaches based on TLR activation.
Literature
1.
Bertoletti A, Gehring AJ (2006) The immune response during hepatitis B virus infection. J Gen Virol 87:1439–1449PubMedCrossRef
2.
Roggendorf M, Lu M (2005) Woodchuck hepatitis virus. In: Thomas TH, Zuckermann A, Lemon A (eds) Viral hepatitis, 3rd edn. Blackwell Publishing Ltd, Oxford, pp 210–224CrossRef
3.
Inchauspé G, Michel ML (2007) Vaccines and immunotherapies against hepatitis B and hepatitis C viruses. J Viral Hepat 14(Suppl 1):97–103PubMedCrossRef
4.
Lu M, Menne S, Yang D, Xu Y, Roggendorf M (2007) Immunomodulation as an option for the treatment of chronic hepatitis B virus infection: preclinical studies in the woodchuck model. Expert Opin Investig Drugs 16:787–801PubMedCrossRef
5.
6.
Mancini-Bourgine M, Fontaine H, Scott-Algara D, Pol S, Brechot C, Michel ML (2004) Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology 40:874–882PubMedCrossRef
7.
Xu DZ, Wang XY, Shen XL, Gong GZ, Ren H, Guo LM, Sun AM, Xu M, Li LJ, Guo XH, Zhen Z, Wang HF, Gong HY, Xu C, Jiang N, Pan C, Gong ZJ, Zhang JM, Shang J, Xu J, Xie Q, Wu TF, Huang WX, Li YG, Xu J, Yuan ZH, Wang B, Zhao K, Wen YM, YIC Efficacy Trial Study Team (2013) Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings. J Hepatol 59:450–456PubMedCrossRef
8.
Fontaine H, Kahi S, Chazallon C, Bourgine M, Varaut A, Buffet C, Godon O, Meritet JF, Saïdi Y, Michel ML, Scott-Algara D, Aboulker JP, Pol S, ANRS HB02 study group (2015) Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial–ANRS HB02 VAC-ADN. Gut 64:139–147PubMedCrossRef
9.
Kosinska AD, Zhang E, Johrden L, Liu J, Seiz PL, Zhang X, Ma Z, Kemper T, Fiedler M, Glebe D, Wildner O, Dittmer U, Lu M, Roggendorf M (2013) Combination of DNA prime–adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model. PLoS Pathog 9:e1003391. doi:10.​1371/​journal.​ppat.​1003391 PubMedCentralPubMedCrossRef
10.
11.
12.
Aderem A, Ulevitch RJ (2000) Toll-like receptors in the induction of the innate immune response. Nature 406:782–787PubMedCrossRef
13.
Gay NJ, Gangloff M (2007) Structure and function of Toll receptors and their ligands. Annu Rev Biochem 76:141–165PubMedCrossRef
14.
15.
Schwabe RF, Seki E, Brenner DA (2006) Toll-like receptor signaling in the liver. Gastroenterology 130:1886–1900PubMedCrossRef
16.
Seki E, Brenner DA (2008) Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 48:322–335PubMedCrossRef
17.
Lee MS, Kim YJ (2007) Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu Rev Biochem 76:447–480PubMedCrossRef
18.
19.
20.
Broering R, Lu M, Schlaak JF (2011) Role of Toll-like receptors in liver health and disease. Clin Sci (Lond) 121:415–426CrossRef
21.
Chang J, Block TM, Guo JT (2012) The innate immune response to hepatitis B virus infection: implications for pathogenesis and therapy. Antivir Res 96:405–413PubMedCrossRef
22.
Wieland S, Thimme R, Purcell RH, Chisari FV (2004) Genomic analysis of the hostresponse to hepatitis B virus infection. Proc Natl Acad Sci U S A 101:6669–6674PubMedCentralPubMedCrossRef
23.
Su AI, Pezacki JP, Wodicka L, Brideau AD, Supekova L, Thimme R, Wieland S, Bukh J, Purcell RH, Schultz PG, Chisari FV (2002) Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A99:15669–15674CrossRef
24.
Dunn C, Peppa D, Khanna P, Nebbia G, Jones M, Brendish N, Lascar RM, Brown D, Gilson RJ, Tedder RJ, Dusheiko GM, Jacobs M, Klenerman P, Maini MK (2009) Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 137:1289–1300PubMedCrossRef
25.
Hösel M, Quasdorff M, Wiegmann K, Webb D, Zedler U, Broxtermann M, Tedjokusumo R, Esser K, Arzberger S, Kirschning CJ, Langenkamp A, Falk C, Büning H, Rose-John S, Protzer U (2009) Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology 50:1773–1782PubMedCrossRef
26.
Wu J, Lu M, Meng Z, Trippler M, Broering R, Szczeponek A, Krux F, Dittmer U, Roggendorf M, Gerken G, Schlaak JF (2007) Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology 46:1769–1778PubMedCrossRef
27.
Wieland SF, Guidotti LG, Chisari FV (2000) Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J Virol 74:4165–4173PubMedCentralPubMedCrossRef
28.
29.
Wieland SF, Eustaquio A, Whitten-Bauer C, Boyd B, Chisari FV (2005) Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids. Proc Natl Acad Sci U S A 102:9913–9917PubMedCentralPubMedCrossRef
30.
Pei R, Chen X, Lu M (2014) Control of hepatitis B virus replication by interferons and Toll-like receptor signaling pathways. World J Gastroenterol 20:11618–11629PubMedCentralPubMedCrossRef
31.
Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, Sprinzl MF, Koppensteiner H, Makowska Z, Volz T, Remouchamps C, Chou WM, Thasler WE, Durantel D, Hüser N, Liang TJ, Münk C, Heim MH, Browning JL, Dejardin E, Schindler M, Dandri M, Heikenwalder M, Protzer U (2014) Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 343:1221–1228PubMedCrossRef
32.
Wu J, Meng Z, Jiang M, Zhang E, Trippler M, Broering R, Bucchi A, Krux F, Dittmer U, Yang D, Roggendorf M, Gerken G, Lu M, Schlaak JF (2010) Toll-like receptor-induced innate immune responses in non-parenchymal liver cells are cell type-specific. Immunology 129:363–374PubMedCentralPubMedCrossRef
33.
Jiang M, Broering R, Trippler M, Poggenpohl L, Fiedler M, Gerken G, Lu M, Schlaak JF (2014) Toll-like receptor-mediated immune responses are attenuated in the presence of high levels of hepatitis B virus surface antigen. J Viral Hepat. doi:10.​1111/​jvh.​12216
34.
Pasquetto V, Wieland SF, Uprichard SL, Tripodi M, Chisari FV (2002) Cytokine-sensitive replication of hepatitis B virus in immortalized mouse hepatocyte cultures. J Virol 76:5646–5653PubMedCentralPubMedCrossRef
35.
Wu J, Meng Z, Jiang M, Pei R, Trippler M, Broering R, Bucchi A, Sowa JP, Dittmer U, Yang D, Roggendorf M, Gerken G, Lu M, Schlaak JF (2009) Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology 49:1132–1140PubMedCrossRef
36.
Shi B, Ren G, Hu Y, Wang S, Zhang Z, Yuan Z (2012) HBsAg inhibits IFN-α production in plasmacytoid dendritic cells through TNF-α and IL-10 induction in monocytes. PLoS One 7:e44900PubMedCentralPubMedCrossRef
37.
Wang H, Ryu WS (2010) Hepatitis B virus polymerase blocks pattern recognitionreceptor signaling via interaction with DDX3: implications for immune evasion. PLoS Pathog 6:e1000986PubMedCentralPubMedCrossRef
38.
Yu S, Chen J, Wu M, Chen H, Kato N, Yuan Z (2010) Hepatitis B virus polymerase inhibits RIG-I- and Toll-like receptor 3-mediated beta interferon induction in human hepatocytes through interference with interferon regulatory factor 3 activation and dampening of the interaction between TBK1/IKKepsilon and DDX3. J Gen Virol 91:2080–2090PubMedCrossRef
39.
Wu M, Xu Y, Lin S, Zhang X, Xiang L, Yuan Z (2007) Hepatitis B virus polymerase inhibits the interferon-inducible MyD88 promoter by blocking nuclear translocation of Stat1. J Gen Virol 88:3260–3269PubMedCrossRef
40.
Chen J, Wu M, Zhang X, Zhang W, Zhang Z, Chen L, He J, Zheng Y, Chen C, Wang F, Hu Y, Zhou X, Wang C, Xu Y, Lu M, Yuan Z (2013) Hepatitis B virus polymerase impairs interferon-α-induced STATs activation through inhibition of importin-α5 and protein kinase C-δ. Hepatology 57:470–482PubMedCrossRef
41.
Kumar M, Jung SY, Hodgson AJ, Madden CR, Qin J, Slagle BL (2011) Hepatitis B virus regulatory HBx protein binds to adaptor protein IPS-1 and inhibits the activation of beta interferon. J Virol 85:987–995PubMedCentralPubMedCrossRef
42.
Wei C, Ni C, Song T, Liu Y, Yang X, Zheng Z, Jia Y, Yuan Y, Guan K, Xu Y, Cheng X, Zhang Y, Yang X, Wang Y, Wen C, Wu Q, Shi W, Zhong H (2010) The hepatitis B virus X protein disrupts innate immunity by down regulating mitochondrial antiviral signaling protein. J Immunol 185:1158–1168PubMedCrossRef
43.
Huang YW, Lin SC, Wei SC, Hu JT, Chang HY, Huang SH, Chen DS, Chen PJ, Hsu PN, Yang SS, Kao JH (2013) Reduced Toll-like receptor 3 expression in chronic hepatitis B patients and its restoration by interferon therapy. Antivir Ther 18:877–884PubMedCrossRef
44.
Lu Y, Xu Y, Yang D, Kemper T, Roggendorf M, Lu M (2008) Molecular characterization of woodchuck type I interferons and their expression by woodchuck peripheral blood lymphocytes. Cytokine 41:127–135PubMedCrossRef
45.
Zhang X, Meng Z, Qiu S, Xu Y, Yang D, Schlaak JF, Roggendorf M, Lu M (2009) Lipopolysaccharide-induced innate immune responses in primary hepatocytes downregulates woodchuck hepatitis virus replication via interferon-independent pathways. Cell Microbiol 11:1624–1637PubMedCrossRef
46.
Thompson AJ, Colledge D, Rodgers S, Wilson R, Revill P, Desmond P, Mansell A, Visvanathan K, Locarnini S (2009) Stimulation of the interleukin-1 receptor and Toll-like receptor 2 inhibits hepatitis B virus replication in hepatoma cell lines in vitro. Antivir Ther 14:797–808PubMedCrossRef
47.
Zhang X, Ma Z, Liu H, Liu J, Meng Z, Broering R, Yang D, Schlaak JF, Roggendorf M, Lu M (2012) Role of Toll-like receptor 2 in the immune response against hepadnaviral infection. J Hepatol 57:522–528PubMedCrossRef
48.
Preiss S, Thompson A, Chen X, Rodgers S, Markovska V, Desmond P, Visvanathan K, Li K, Locarnini S, Revill P (2008) Characterization of the innate immune signalling pathways in hepatocyte cell lines. J Viral Hepat 15:888–900PubMedCrossRef
49.
Xu Y, Kock J, Lu Y, Yang D, Lu M, Zhao X (2011) Suppression of hepatitis B virus replication in Tupaia hepatocytes by tumor necrosis factor alpha of Tupaia belangeri. Comp Immunol Microbiol Infect Dis 34:361–368PubMedCrossRef
50.
Visvanathan K, Skinner NA, Thompson AJ, Riordan SM, Sozzi V, Edwards R, Rodgers S, Kurtovic J, Chang J, Lewin S, Desmond P, Locarnini S (2007) Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology 45:102–110PubMedCrossRef
51.
Lang T, Lo C, Skinner N, Locarnini S, Visvanathan K, Mansell A (2011) The hepatitis B e antigen (HBeAg) targets and suppresses activation of the toll-like receptor signaling pathway. J Hepatol 55:762–769PubMedCrossRef
52.
Chen Z, Cheng Y, Xu Y, Liao J, Zhang X, Hu Y, Zhang Q, Wang J, Zhang Z, Shen F, Yuan Z (2008) Expression profiles and function of Toll-like receptors 2 and 4 in peripheral blood mononuclear cells of chronic hepatitis B patients. Clin Immunol 128:400–408PubMedCrossRef
53.
Böttcher JP, Schanz O, Wohlleber D, Abdullah Z, Debey-Pascher S, Staratschek-Jox A, Höchst B, Hegenbarth S, Grell J, Limmer A, Atreya I, Neurath MF, Busch DH, Schmitt E, van Endert P, Kolanus W, Kurts C, Schultze JL, Diehl L, Knolle PA (2013) Liver-primed memory T cells generated under noninflammatory conditions provide anti-infectious immunity. Cell Rep 3:779–795PubMedCrossRef
54.
Kern M, Popov A, Scholz K, Schumak B, Djandji D, Limmer A, Eggle D, Sacher T, Zawatzky R, Holtappels R, Reddehase MJ, Hartmann G, Debey-Pascher S, Diehl L, Kalinke U, Koszinowski U, Schultze J, Knolle PA (2010) Virally infected mouse liver endothelial cells trigger CD8+ T-cell immunity. Gastroenterology 138:336–346PubMedCrossRef
55.
Liu J, Jiang M, Ma Z, Dietze KK, Zelinskyy G, Yang D, Dittmer U, Schlaak JF, Roggendorf M, Lu M (2013) TLR1/2 ligand-stimulated mouse liver endothelial cells secrete IL-12 and trigger CD8+ T cell immunity in vitro. J Immunol 191:6178–6190PubMedCrossRef
56.
Wang S, Chen Z, Hu C, Qian F, Cheng Y, Wu M, Shi B, Chen J, Hu Y, Yuan Z (2013) Hepatitis B virus surface antigen selectively inhibits TLR2 ligand-induced IL-12 production in monocytes/macrophages by interfering with JNK activation. J Immunol 190:5142–5151PubMedCrossRef
57.
Zhang X, Kraft A, Boering R, Schlaak JF, Dittmer U, Lu M (2012) Preclinical development of TLR ligands as drugs for the treatment of chronic viral infection. Expert Opin Drug Discov 7:561–597CrossRef
58.
Krieg AM (2002) CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20:709–760PubMedCrossRef
59.
Vollmer J, Weeratna R, Payette P, Jurk M, Schetter C, Laucht M, Wader T, Tluk S, Liu M, Davis HL, Krieg AM (2004) Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 34:251–262PubMedCrossRef
60.
Menne S, Tennant BC, Liu KH, Ascenzi MA, Baldwin BH, Bellezza CA, Cote PJ, Zheng X, Wolfgang G, Turnas D (2011) Anti-viral efficacy and induction of an antibody response against surface antigen with the TLR7 Agonist GS-9620 in the Woodchuck Model of Chronic HBV Infection. J Hepatol 54:S441CrossRef
61.
Lanford RE, Guerra B, Chavez DC, Hodara VL, Zheng X, Wolfgang G, Tumas D (2011) Therapeutic efficacy of a TLR7 agonist for HBV chronic infection in chimpanzees. J Hepatol 54:S45CrossRef
62.
Romagne F (2007) Current and future drugs targeting one class of innate immunity receptors: the Toll-like receptors. Drug Discov Today 12:80–87PubMedCrossRef
63.
Evans JT, Cluff CW, Johnson DA, Lacy MJ, Persing DH, Baldridge JR (2003) Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi. 529. Expert Rev Vaccines 2:219–229PubMedCrossRef
64.
Dupont J, Altclas J, Lepetic A, Lombardo M, Vázquez V, Salgueira C, Seigelchifer M, Arndtz N, Antunez E, von Eschen K, Janowicz Z (2006) A controlled clinical trial comparing the safety and immunogenicity of a new adjuvanted hepatitis B vaccine with a standard hepatitis B vaccine. Vaccine 24:7167–7174PubMedCrossRef
65.
Kanzler H, Barrat FJ, Hessel EM, Coffman RL (2007) Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 13:552–559PubMedCrossRef
66.
Sablan BP, Kim DJ, Barzaga NG, Chow WC, Cho M, Ahn SH, Hwang SG, Lee JH, Namini H, Heyward WL (2012) Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine. Vaccine 30:2689–2696PubMedCrossRef
67.
Cooper C, Mackie D (2011) Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine: a review of HEPLISAV safety and efficacy. Expert Rev Vaccines 10:417–427PubMedCrossRef
68.
69.
Wu J, Chen M, Lin Y, Xia Y, Sun C, Wang J, Guo Y, Song J, Zhang E, Wang B, Zhen X, Schlaak JF, Lu M, Yang D (2014) Polyinosinic-polycytidylic acid (polyIC) treatment leads to the interferon-dependent clearance of hepatitis B virus in hydrodynamic injection mouse mode. J Virol 88:10421–10431PubMedCrossRef
70.
Cottalorda A, Verschelde C, Marcais A, Tomkowiak M, Musette P, Uematsu S, Akira S, Marvel J, Bonnefoy-Berard N (2006) TLR2 engagement on CD8 T cells lowers the threshold for optimal antigen-induced T cell activation. Eur J Immunol 36:1684–1693PubMedCrossRef
71.
Geng D, Zheng L, Srivastava R, Asprodites N, Velasco-Gonzalez C, Davila E (2010) When Toll-like receptor and T-cell receptor signals collide: a mechanism for enhanced CD8 T-cell effector function. Blood 116:3494–3504PubMedCentralPubMedCrossRef
72.
Komai-Koma M, Jones L, Ogg GS, Xu D, Liew FY (2004) TLR2 is expressed on activated T cells as a costimulatory receptor. Proc Natl Acad Sci U S A 101:3029–3034PubMedCentralPubMedCrossRef
73.
Mercier BC, Cottalorda A, Coupet CA, Marvel J, Bonnefoy-Berard N (2009) TLR2 engagement on CD8 T cells enables generation of functional memory cells in response to a suboptimal TCR signal. J Immunol 182:1860–1867PubMedCrossRef
74.
Asprodites N, Zheng L, Geng D, Velasco-Gonzalez C, Sanchez-Perez L, Davila E (2008) Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity. FASEB J 22:3628–3637PubMedCentralPubMedCrossRef
75.
Geng D, Zheng L, Srivastava R, Velasco-Gonzalez C, Riker A, Markovic SN, Davila E (2010) Amplifying TLR-MyD88 signals within tumor-specific T cells enhances antitumor activity to suboptimal levels of weakly immunogenic tumor antigens. Cancer Res 70:7442–7454PubMedCentralPubMedCrossRef
76.
Deres K, Schild H, Wiesmüller KH, Jung G, Rammensee HG (1989) In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature 342:561–564PubMedCrossRef
77.
Heathcote J, McHutchison J, Lee S, Tong M, Benner K, Minuk G, Wright T, Fikes J, Livingston B, Sette A, Chestnut R (1999) A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group. Hepatology 30:531–536PubMedCrossRef
78.
Jackson DC, Lau YF, Le T, Suhrbier A, Deliyannis G, Cheers C, Smith C, Zeng W, Brown LE (2004) A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci U S A 101:15440–15445PubMedCentralPubMedCrossRef
79.
Vitiello A, Ishioka G, Grey HM, Rose R, Farness P, LaFond R, Yuan L, Chisari FV, Furze J, Bartholomeuz R et al (1995) Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest 95:341–349PubMedCentralPubMedCrossRef
Metadata
Title
Toll-like receptor (TLR)-mediated innate immune responses in the control of hepatitis B virus (HBV) infection
Authors
Ejuan Zhang
Mengji Lu
Publication date
01-02-2015
Publisher
Springer Berlin Heidelberg
Published in
Medical Microbiology and Immunology / Issue 1/2015
Print ISSN: 0300-8584
Electronic ISSN: 1432-1831
DOI
https://doi.org/10.1007/s00430-014-0370-1

Other articles of this Issue 1/2015

Medical Microbiology and Immunology 1/2015 Go to the issue

Review

Antiviral therapy for chronic hepatitis B in China

Review

Natural history of chronic hepatitis B virus infection

Review

The role of hepatic immune regulation in systemic immunity to viral infection

Review

Therapeutic vaccines in treating chronic hepatitis B: the end of the beginning or the beginning of the end?

Review

Electroporation for therapeutic DNA vaccination in patients

Review

Old and new adjuvants for hepatitis B vaccines

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits